Author | Mark Fuerst

Articles

Direct-acting antiviral combination retreats chronic hepatitis C failures

Article

Sofosbuvir-velpatasvir-voxilaprevir provides salvage therapy for NS5A failures

More than one-third of hepatitis C patients denied insurance coverage

Article

Despite the availability of new, highly successful direct-acting antiviral (DAA) regimens, more than one third of chronic hepatitis C (HCV) patients are denied access to treatment by their insurance provider, according to a new study.